Rani Therapeutics Holdings, Inc. Class A RANI

SAN JOSE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s management team will participate in the upcoming September conferences. 10th Annual Best Ideas Growth (BIG10) Conference hosted by Lake Street Capital MarketsDate: Thursday, September 10, 2026 Format: 1x1 MeetingsLocation: New York, NY H.C. Wainwright 28th Annual Global Investment C

Looking for biotech stocks with upside that could help people fight illness? Here are three that analysts think might be worth a look.

~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026 ~ ~ Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing ~ ~ Completed a $20 million registered direct offering ~ ~ Expanded obesity pipeline through new research and development collaboration with PegBio to explore oral delivery of novel o

~ Former Chief Financial Officer of Arcellx Brings Deep Capital Markets and Biotech Financial Leadership Experience ~SAN JOSE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced the appointment of Michelle Gilson to its Board of Directors. Ms. Gilson will serve as Chair of the Audit Committee. "The combination of deep capital markets expertise and hands-on finan

SAN JOSE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported that it granted an equity award in the form of a stock option to purchase 2,000,000 shares of Rani Class A common stock to Nicholas Maestas, Rani’s new Chief Financial Officer, as an inducement material to his acceptance of employment with Ran

RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with the GLP-1/GLP-2 agonist class of therapeuticsPhase 1a study expanded with an additional cohort to further define the oral-to-subcutaneous pharmacokinetic relationship ahead of a planned Phase 1b repeat-dose study in patients with obesity SAN JOSE, Calif., July 15, 2026 (GLOBE NEWS

~ Collaboration will leverage the RaniPill® platform to explore oral delivery of PegBio's proprietary portfolio of novel obesity and metabolic disease molecules ~ ~ Agreement expands Rani's obesity franchise beyond its existing programs, potentially adding multiple new candidates across differentiated mechanisms of action ~ SAN JOSE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company

SAN JOSE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Nicholas Maestas as Chief Financial Officer, effective immediately. “We are pleased to welcome Nicholas as our new Chief Financial Officer,” said Talat Imran, Chief Executive Officer of Rani. “His depth of experience in bio

SAN JOSE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement led by a sovereign wealth fund, along with other new and existing healthcare-focused funds for the purchase and sale of 12,476,637 shares of Rani Therapeutics’ Class A common stock at a purchase price

- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen – - Appointed Alireza Javadi, Ph.D. as Chief Technical Officer - - Appointed Jesper Høiland as Head of Strategy and Dr. Sara Kenkare-Mitra as a Strategic Advisor – SAN JOSE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the or

SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s management team will participate in the upcoming H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. Details below: H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQDate: Tuesday, May 19, 2026 at 10:00 am